Pharmiweb
AVOS Life Sciences
Posted on:19 Aug 08

MORRISVILLE, N.C. (Aug. 18, 2008) - AVOS Life Sciences contends that Tysabri will exceed $1 billion in sales by 2014 as previously forecasted in the AVOS Therapeutic Market Outlook (TMO) Multiple Sclerosis Report released on July 1, 2008. In addition, the market dynamics featured in the report remain the same despite the recent cases of progressive multifocal leukoencephalopathy (PML) associated with Tysabri.

» Read More